In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications

K Huang, D Zapata, Y Tang, Y Teng, Y Li - Biomaterials, 2022 - Elsevier
Since its mechanism discovery in 2012 and the first application for mammalian genome
editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created …
被引用次数：27 相关文章

In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications

K Huang, D Zapata, Y Tang, Y Teng, Y Li - Biomaterials, 2022 - pubmed.ncbi.nlm.nih.gov
Since its mechanism discovery in 2012 and the first application for mammalian genome
editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created …
[HTML] nih.gov

[HTML][HTML] In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications

K Huang, D Zapata, Y Tang, Y Teng, Y Li - Biomaterials, 2022 - ncbi.nlm.nih.gov
Since its mechanism discovery in 2012 and the first application for mammalian genome
editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created …

In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.

K Huang, D Zapata, Y Tang, Y Teng, Y Li - Biomaterials, 2022 - europepmc.org
Since its mechanism discovery in 2012 and the first application for mammalian genome
editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created …

In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.

K Huang, D Zapata, Y Tang, Y Teng, Y Li - Biomaterials, 2022 - europepmc.org
Since its mechanism discovery in 2012 and the first application for mammalian genome
editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created …